Amneal Pharmaceuticals, INC 8-K filings

Amneal Pharmaceuticals announced the completion of its acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars leader.

Amneal Pharmaceuticals announced that its stockholders have approved the acquisition of Kashiv BioSciences, LLC, with the transaction expected to close in the second half of 2026.

Amneal Pharmaceuticals announced strong second quarter 2026 results, exceeding expectations with a 10% revenue increase and raising full-year guidance, driven by growth in specialty and affordable medicines.

Amneal Pharmaceuticals announced first quarter 2026 results with net revenue of $723 million, a 4% increase year-over-year, and affirmed its full-year 2026 guidance.

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for $375 million in cash and stock, plus potential milestone and royalty payments, aiming to bolster its global biosimilar capabilities and reported strong preliminary Q1 2026 results.

Amneal Pharmaceuticals announced strong fourth quarter and full year 2025 financial results, meeting or exceeding all guidance metrics and projecting continued growth for 2026.

Amneal Pharmaceuticals, Inc. has finalized a nationwide agreement to settle a substantial majority of opioid-related claims, involving $88.5 million in cash and up to $177.4 million in naloxone nasal spray.

Amneal Pharmaceuticals, Inc. announced it expects to meet or exceed its 2025 full-year financial guidance and reduce net leverage.

Amneal Pharmaceuticals announced robust third-quarter 2025 financial results, including a 12% revenue increase and improved full-year guidance, driven by specialty and affordable medicines growth.

Amneal Pharmaceuticals, Inc. announced its Board of Directors will hold future Say-on-Pay votes annually, aligning with stockholder preference.

Amneal Pharmaceuticals reports strong second quarter 2025 financial results, raises full-year guidance, and successfully completes a comprehensive debt refinancing.

Amneal Pharmaceuticals LLC, a subsidiary of Amneal Pharmaceuticals, Inc., successfully refinanced its existing debt by securing a new $2.1 billion term loan and issuing $600 million in senior secured notes, while also extending its ABL facility's maturity.

Amneal Pharmaceuticals' subsidiary priced $600 million in senior secured notes and upsized its new term B loans to $2.1 billion, with proceeds intended to refinance existing debt and repay ABL facility borrowings.

Amneal Pharmaceuticals' subsidiary, Amneal Pharmaceuticals LLC, announced plans to raise $2.55 billion through new term B loans and senior secured notes to refinance existing debt and repay ABL facility amounts.

Amneal Pharmaceuticals, Inc. announced robust preliminary second quarter 2025 financial results, showcasing continued financial strength, significant deleveraging, and key product advancements.

Amneal Pharmaceuticals successfully held its 2025 Annual Meeting of Stockholders on May 6, 2025, with all proposals approved and director nominees elected.

Amneal Pharmaceuticals announces a robust first quarter in 2025, marked by revenue growth and increased profitability, while reaffirming its financial outlook for the year.

Amneal Pharmaceuticals formalizes Jason Daly's promotion to Executive Vice President, Chief Legal Officer & Corporate Secretary with a new employment agreement effective March 1, 2025.

Amneal Pharmaceuticals announces positive Q4 and full year 2024 financial results, meeting or exceeding all financial guidance metrics and providing 2025 guidance.

Amneal Pharmaceuticals anticipates meeting or surpassing its full-year 2024 financial guidance, including exceeding operating cash flow and capital expenditure targets.

Amneal Pharmaceuticals announced a 13% increase in net revenue for Q3 2024, reaching $702 million, alongside strategic growth initiatives.

Amneal Pharmaceuticals announced a 13% increase in net revenue for Q3 2024, driven by growth across its generics, specialty, and AvKARE segments, while affirming its full-year guidance.

Amneal Pharmaceuticals and Metsera, Inc. have announced a strategic collaboration to develop and supply a portfolio of new weight loss medicines globally.

Amneal Pharmaceuticals reported a 17% increase in revenue for the second quarter of 2024 and received FDA approval for its Parkinson's disease treatment, CREXONT.

Amneal Pharmaceuticals successfully held its 2024 Annual Meeting of Stockholders, electing all director nominees and approving all proposals.

Amneal Pharmaceuticals announced record first-quarter revenue of $659 million, driven by double-digit growth across all business segments, while also reaching a settlement in principle regarding opioid litigation.

Amneal Pharmaceuticals announced its fourth quarter and full year 2023 financial results, showing revenue growth but also a net loss, and provided financial guidance for 2024.